Allergan may sell faltering obesity unit; Takeda's lymphoma drug Adcetris wins EU nod;

@FiercePharma: BMJ says no more clinical trial publications if actual data isn't open for outside review. More | Follow @FiercePharma

> Allergan ($AGN) is mulling the sale of its obesity business after Lap-Band sales dropped 21% for the third quarter; the company's profits managed to beat expectations on a 6% rise in overall sales. Report

> AstraZeneca ($AZN) says it will relax restrictions on employee travel and partipation in industry conferences. Report

> European regulators granted conditional approval to Takeda Pharmaceutical's non-Hodgkin lymphoma drug Adcetris, recently launched in the U.S. Report

> Stringent austerity measures will deliver a 15% savings in Spain's drug spending, which, together with unpaid pharma bills, has pushed the industry to "the brink of collapse," Farmaindustria says. Report

> Roche's ($RHHBY) Avastin won a new ovarian cancer indication from European regulators. Report

> The European Medicines Agency expanded use of Eli Lilly's ($LLY) erectile dysfunction drug Cialis to patients with enlarged-prostate symptoms. Report

> Poland's pharma market will lose steam this year, as new pricing policies send growth into negative territory. Report

> U.S. Centers for Disease Control and Prevention added three to the death toll in the ongoing meningitis outbreak linked to compounded drugs; it's now 28. Report

Medical Device News

 @FierceMedDev: Boston Sci snagged EU approval for its new stent with bioabsorbable coating. News | Follow @FierceMedDev

 @MarkHFierce: Fidelity is investing $75M into Trivitron Healthcare, an Indian company focused on imaging and lab Dx. Release | Follow @MarkHFierce

 @DamianFierce: The latest Cleveland Clinic top 10 innovations list includes some novel medical devices. Article | Follow @DamianFierce

> GI Dynamics moves toward FDA approval for weight-loss tech. Story

> OptiScan, maker of glucose monitoring devices, raises $2.6M. Item

Biotech News

 @FierceBiotech: Ipsen braces for $153M write-off as troubled biotech partner declares bankruptcy. News | Follow @FierceBiotech

 @JohnCFierce: Biocon (India) scouts R&D pact after GE unit grabs stake in research division. Story | Follow @JohnCFierce

 @RyanMFierce: Biotech's boneyard: 2012 report on the dead, dying, disabled (and some reborn) biotech operations. Happy Halloween! Special Report | Follow @RyanMFierce

> Researchers nab $11M to fund second look at AstraZeneca's stockpile of failed drugs. Article

> Biogen streak lives on with upbeat PhIII results for hemophilia A therapy. Story

Drug Delivery News

> Twice-yearly opioid dependence implant steps closer to the market. Item

> Ocular Therapeutix eyes up positive results for OTX-TP2. Article

> Starpharma technology delivers 40-fold more docetaxel to tumor. Report

> Paclitaxel particles extend life threefold in mouse bladder cancer. News

Biomarkers News

> Seeing is believing: Biomarkers visible to the naked eye. Item

> Blood biomarker tags NeuVax's role in breast cancer treatment. Article

> Marking glimpses of activity for Lilly's Alzheimer drug after PhIII struggles. Report

> U.K. researchers spot new marker for prostate cancer prognosis. News

> Chromosome cap length predicts pancreatic cancer risk. Story

And Finally... Diabetes rates are soaring in Saudi Arabia as the government is pledging billions to improve healthcare. Report


Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.